Silence Therapeutics PLC First dosing for SLN360 (3950P)
February 17 2021 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 3950P
Silence Therapeutics PLC
17 February 2021
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial
of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
17 February 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that it has started
dosing subjects in the APOLLO Phase I clinical study of its wholly
owned lead product candidate, SLN360, for the treatment of elevated
Lipoprotein (a) - or Lp(a) - levels.
This first-in-human study is investigating the safety,
tolerability, pharmacokinetic and pharmacodynamic response of
SLN360 in people with elevated Lp(a) levels approximately >=60
mg/dL. The APOLLO trial is a global, randomized, double-blind,
placebo controlled, single-ascending and multiple-ascending dose
study enrolling approximately 88 subjects total in up to nine
cohorts.
Silence intends to report data from the single-ascending dose
portion of the study in the second half of this year.
More information on the SLN360 APOLLO trial can be found
here.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/ Angela Gray / Chris Welsh
silencetherapeutics@consilium-comms.com
About SLN360
Silence's wholly owned lead product candidate, SLN360, is a gene
'silencing' therapy - one that is designed to temporarily block a
specific gene's message that would otherwise trigger an unwanted
effect. In this case, it aims to 'silence' LPA, a gene that tells
the body to make a specific protein that is only found in Lp(a). By
silencing LPA, the levels of Lp(a) are lowered, which in turn is
expected to lower the risk of heart diseases, heart attacks and
strokes.
About Lipoprotein(a)
Lipoprotein(a), known as Lp(a) for short, is a particle made by
the liver, which consists of cholesterol, fats and proteins. Most
people have some Lp(a) in their body, but about 1 in 5 people have
high levels of Lp(a), because of a specific gene variation in their
DNA. Most people are unaware if they have elevated Lp(a). People
living with elevated Lp(a) have a higher risk of developing early
heart disease, heart attacks and strokes. Most standard cholesterol
tests do not currently include screening for Lp(a). Current
medicines that are used to lower other lipid levels in the blood do
not have a meaningful effect on Lp(a) and are less effective
overall in people with high levels of Lp(a).
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary messenger RNAi GOLD(TM) (GalNAc
Oligonucleotide Discovery) Platform can be used to create siRNAs
that precisely target and silence disease-associated genes in the
liver, which represents a substantial opportunity. Silence's wholly
owned product candidates include SLN360 designed to address the
high and prevalent unmet medical need in reducing cardiovascular
risk in people born with high levels of lipoprotein(a) and SLN124
designed to address iron loading anemias. Silence also maintains
ongoing research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements, including with respect to the Company's clinical
development timeline and commercial prospects. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including the
potential impact of COVID-19 on the Company's clinical development
and regulatory timelines and plans. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFISMWEFSELE
(END) Dow Jones Newswires
February 17, 2021 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024